Heparin and LMW heparin: Dosing and adverse effects
Heparin and LMW heparin: Dosing and adverse effects
UpToDate
We identified five common practices that led to delays in achieving a PTT greater than 1.5 times the laboratory control: (1) failure to start heparin therapy at the time of initial clinical suspicion, (2) choice of a heparin sodium bolus (mean, 5861 +/- 365 U) and continuous infusion (1026 +/- 148 U/h) insufficient to elevate the PTT to greater ...
Rapid overview: Management of STEMI or NSTEACS - UpToDate
Dosing of UFH: An initial IV bolus of 50 to 70 units/kg up to a maximum of 5000 units. Additional heparin may be given in the catheterization laboratory based on the results of ACT monitoring. Dosing of bivalirudin: Initial bolus of 0.75 mg/kg IV followed by IV infusion of 1.75 mg/kg per hour; can be discontinued after PCI.
Blood management and anticoagulation for cardiopulmonary bypass
2024年7月10日 · After weaning from CPB, protamine administration to reverse systemic heparin anticoagulation and management of postbypass bleeding are discussed in separate topics.
UpToDate
With an empirically developed algorithm, the HeProCalc program, heparin, and protamine doses are calculated during the procedure. The primary aim was to investigate whether HeProCalc-based dosage of heparin could reduce protamine use compared with traditional dosages.
UpToDate
Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse effect of heparin that is important because of its relatively high frequency and its strong association with paradoxic venous and arterial thrombosis.
Protamine: Administration and management of adverse
2023年2月28日 · Protamine sulfate is routinely administered to reverse the systemic anticoagulation effects of unfractionated heparin (UFH) after cardiac surgery or surgical and percutaneous vascular procedures. There are no alternative agents to reverse UFH.
Anticoagulation for the hemodialysis procedure - UpToDate
2024年1月30日 · Thus, some form of anticoagulation (eg, unfractionated heparin [UFH]) is typically administered at the time of dialysis to prevent clotting in the blood circuit. This topic discusses anticoagulation for intermittent HD delivered in the setting of acute kidney injury or end-stage kidney disease.
UpToDate
Data collected included initiation and maintenance doses of heparin, frequency of monitoring and dose adjustments, time to the therapeutic range, complications and interruptions of therapy, and characteristics of heparin-to-warfarin transition.
肝素和低分子量肝素的用法用量和不良反应 - UpToDate
引言. 肝素包括普通肝素和多种低分子量(low molecular weight, LMW)肝素产品，被广泛用于抗凝。本专题将总结普通肝素和低分子量肝素治疗性应用的一般原则，包括用法用量、监测和逆转抗凝作用，以及达那帕罗(在美国不能使用)相关内容。